Legend Biotech (NASDAQ:LEGN – Get Free Report) and BioStem Technologies (OTCMKTS:BSEM – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current ratings for Legend Biotech and BioStem Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Legend Biotech | 1 | 5 | 9 | 0 | 2.53 |
| BioStem Technologies | 0 | 1 | 0 | 1 | 3.00 |
Legend Biotech presently has a consensus target price of $55.29, indicating a potential upside of 172.25%. BioStem Technologies has a consensus target price of $9.00, indicating a potential upside of 134.07%. Given Legend Biotech’s higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than BioStem Technologies.
Risk & Volatility
Institutional and Insider Ownership
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Legend Biotech and BioStem Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Legend Biotech | $1.03 billion | 3.67 | -$296.80 million | ($0.68) | -29.86 |
| BioStem Technologies | $47.48 million | 1.44 | -$19.79 million | ($1.11) | -3.46 |
BioStem Technologies has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Legend Biotech and BioStem Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Legend Biotech | -21.98% | -24.92% | -14.87% |
| BioStem Technologies | N/A | N/A | N/A |
Summary
Legend Biotech beats BioStem Technologies on 8 of the 15 factors compared between the two stocks.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
